Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 145
- Registration Number
- NCT03233139
- Locations
- 🇯🇵
Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Osaka Medical College Hospital, Takatsuki, Osaka, Japan
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 78
- Registration Number
- NCT03223155
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Alona Zer
- Target Recruit Count
- 20
- Registration Number
- NCT03219671
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Toni Choueiri, MD
- Target Recruit Count
- 85
- Registration Number
- NCT03203473
- Locations
- 🇺🇸
Lifespan Comprehensve Cancer Center, Providence, Rhode Island, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of California, San Diego Moores Cancer Center, La Jolla, California, United States
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 14
- Registration Number
- NCT03203304
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT03195478
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0012, Guangzhou, Guangdong, China
🇨🇳Local Institution - 0020, XiAn, Shan1xi, China
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 61
- Registration Number
- NCT03190265
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2022-02-16
- Target Recruit Count
- 85
- Registration Number
- NCT03177239
- Locations
- 🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Northern Cancer Institute, Frenchs Forest, New South Wales, Australia
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT03172624
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT03168464
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.